Hepatotoxic effects of methotrexate

Evan M. Hersh, Vernon G. Wong, Edward S. Henderson, Emil J. Freireich

Research output: Contribution to journalArticlepeer-review

102 Scopus citations


Hepatotoxicity of methotrexate (MTX) therapy was studied in 22 patients. During intensive MTX therapy, values for SGOT, SGPT, LDH and BSP were 140 μ, 315 μ, 753 μ and 13% with control values of 13.5 μ, 20.5 μ, 379 μ and 4%, respectively. During intermittent therapy these values were 50 μ, 110 μ, 544 μ and 10% with controls of 13 μ, 15 μ, 355 μ and 3%. Other liver function tests remained normal. After cessation of intermittent therapy, recovery occurred in one month. Liver biopsies revealed a chronic portal inflammatory reaction in 7/10. Methotrexate can be used in nonmalignant disorders provided that careful control of its toxic side effects is maintained.

Original languageEnglish (US)
Pages (from-to)600-606
Number of pages7
Issue number4
StatePublished - Apr 1966
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Hepatotoxic effects of methotrexate'. Together they form a unique fingerprint.

Cite this